AIM Vaccine (06660.HK): Marketing Application Submitted for High-Potency Human Diploid Rabies Vaccine with Optimized Manufacturing Process

NewTimeSpace News: On August 24, 2026,AIM Vaccine(06660.HK) announced that the marketing registration application for its self-developed high-potency human diploid rabies vaccine with upgraded manufacturing process has recently been filed with the National Medical Products Administration. According toAIM Vaccine, results from the unblinded Phase III clinical trial demonstrate that the vaccine features favorable safety profile, immunogenicity and immune persistence. It achieves superior immunogenicity and immune persistence compared with the control vaccine of the same category, with all indicators fully meeting the pre-set evaluation criteria of the clinical trial.

As disclosed in the announcement, this product is an upgraded human diploid rabies vaccine with ultra-high potency. It breaks through the technical bottlenecks of low virus titer and low yield in conventional processes and introduces innovations in purification procedures.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.